[A22-126] Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) – Addendum to Commission A22-80
Last updated 03.02.2023
Project no.:
A22-126
Commission:
Commission awarded on 06.12.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Patients with unresectable or metastatic HER2-positive breast cancer who have previously received one HER2-targeted therapy
Result of dossier assessment:
After addendum now:
- Patients < 65 years: hint of major added benefit
- Patients ≥ 65 years: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-80 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-02-02 A G-BA decision was published.